We’ve used a term “reprogramming 3.0” to describe the methodology of induced direct reprogramming (or transdifferentiation) by defined factors in vivo. This is a relatively new and, potentially, groundbreaking technique. It was developed few years ago by researchers working in diabetes field. Let’s look at some important studies in historical context. 2002. Taniguchi proposed to use a transcription factor Pdx-1 to induce insulin production by pancreatic beta-cells. It was quite different from classical gene therapy, because it wasn’t simple replacement [...]
There is a necessity for development of improved potency assays in hematopoietic stem cell (HSC) transplantation clinic. Today I’d like to offer a poll, where you express your opinion on this matter. Background: Potency is defined as the specific capacity of a cellular product to affect a given result. The potency of cell product in HSC transplantation clinic is assessing a function of stem and progenitor cells. The current analogs of potency assays in HSC transplantation clinic are total nucleated [...]
